HDAC3 and acute myeloid leukemia: We argue that a similar mechanism of action is at work in AML, as we found that HDAC3 levels were significantly downregulated in responders to ADE+BTZ after 24 h of treatment, but not in the absence of bortezomib or in patients that were bortezomib resistant and relapsed (Figure S7).